Tu-W20:6 First large randomized trial of statin therapy in South Asian patients at risk for coronary heart disease: The iris trial

Deedwania, P.; M, Gupta; Stein, Michael; Ycas, J.; Gold, Alex

doi:10.1016/s1567-5688(06)80631-8

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study provides more evidence about the effectiveness of rosuvastatin therapy in reducing cardiovascular risk, even among persons who would not currently be considered for pharmacotherapy. Further insights on cardiovascular outcomes will be available by the on‐going trials included in the GALAXY program (27–32).…”

Section: Discussionmentioning

confidence: 99%

“…Specific focus groups include: type‐2 diabetics (27), haemodialysis recipients, patients with congestive heart failure (28,29) and specific ethnic groups. Three prospective studies evaluating rosuvastatin efficacy in under‐represented populations have been presented, namely African American Rosuvastatin Investigation of Efficacy and Safety (30), Study Assessing Rosuvastatin in Hispanic Population (31) and Investigation of Rosuvastatin In South Asian Subjects (32).…”

Section: Quantitative Effects Of Rosuvastatin On Ldl‐cholesterolmentioning

confidence: 99%

See 1 more Smart Citation

Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance?

Rizzo

Berneis

Spinas

et al. 2009

International Journal of Clinical Practice

View full text Add to dashboard Cite

The recent Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin study provides more evidence about the effectiveness of rosuvastatin therapy in reducing cardiovascular risk, even among persons who would not currently be considered for pharmacotherapy. Further insights on cardiovascular outcomes will be available by the on-going trials included in the GALAXY program that includes subjects with type-2 diabetes, haemodialysis recipients, patients with congestive heart failure and specific ethnic groups, such as African American, Hispanic and South Asian populations.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Quantitative Effects Of Rosuvastatin On Ldl‐cholesterolmentioning

confidence: 99%

Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance?

Rizzo

Berneis

Spinas

et al. 2009

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Specific focus groups include: Type II diabetics (Tuomilehto et al 2004), hemodialysis recipients, patients with congestive heart failure (Krum et al 2006; Raina et al 2006) and specific ethnic groups. Three prospective studies evaluating rosuvastatin efficacy in under-represented populations have recently been presented, namely (African American Rosuvastatin Investigation of Efficacy and Safety) (Ferdinand et al 2006), STARSHIP (STudy Assessing RoSuvastatin in HIspanic Population) (Llorett et al 2006), and IRIS (Investigation of Rosuvastatin In South Asian Subjects) (Deedwania et al 2006). …”

Section: Third Generation Statinmentioning

confidence: 99%

Clinical efficacy and safety of statins in managing cardiovascular risk

Kapur

Musunuru²

2008

VHRM

119

View full text Add to dashboard Cite

Abstract:Since their introduction in the 1980s, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have emerged as the one of the best-selling medication classes to date, with numerous trials demonstrating powerful effi cacy in preventing cardiovascular outcomes. As our understanding of low-density lipoprotein cholesterol (LDL-C) and atherosclerosis continues to grow, the concept of 'lower is better' has corresponded with a 'more is better' approach to statin-based therapy. This review provides a detailed understanding of the clinical effi cacy and safety of statins with a particular emphasis on the third generation drug, rosuvastatin.

show abstract

Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease

Kapur

2007

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

Since the identification of a fungal metabolite that inhibits HMG-CoA reductase in 1976, statins have emerged rapidly as the global leader in pharmacotherapeutics designed to lower low-density lipoprotein cholesterol (LDL-C). In conjunction, practice guidelines have recommended increasingly aggressive measures to improve coronary heart disease (CHD) outcomes by lowering LDL-C. By virtue of unique chemical characteristics, enhanced binding thermodynamics and limited cytochrome P450 3A4 metabolism, rosuvastatin calcium has a safety profile in line with currently marketed statins, but a different efficacy profile. Mirroring this chemical profile, the GALAXY program represents a comprehensive evaluation of the efficacy, safety and cost-effectiveness of rosuvastatin in individuals representing various clinical diagnoses, pathophysiological states and ethnicities. Also results from the Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study could provide further evidence for the use of rosuvastatin in individuals with traditional and emerging CHD risk factors, such as an elevated high sensitivity C-reactive protein level. This review will provide a comprehensive evaluation of the chemistry, clinical efficacy, safety and tolerability of rosuvastatin, and discuss the future role in the management of CHD and atherosclerosis.

show abstract

Tu-W20:6 First large randomized trial of statin therapy in South Asian patients at risk for coronary heart disease: The iris trial

Cited by 3 publications

References 0 publications

Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance?

Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance?

Clinical efficacy and safety of statins in managing cardiovascular risk

Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease

Contact Info

Product

Resources

About